Size and shape have progressively appeared as some of the key factors influencing the properties of nanosized drug delivery systems. In particular, elongated materials are thought to interact differently with cells and therefore may allow alterations of in vivo fate without changes in chemical composition. A challenge, however, remains the creation of stable selfassembled materials with anisotropic shape for delivery applications that still feature the ability to disassemble, avoiding organ accumulation and facilitating clearance from the system. In this context, we report on self-assembled cyclic peptide-polymer conjugates that self-assemble into supramolecular nanotubes, as confirmed by SANS and SLS. Their behaviour ex and in vivo was studied: the nanostructures are non-toxic up to a concentration of 0.5 g.L -1 and cell uptake studies revealed that the pathway of entry was energy-dependent. Pharmacokinetic studies following intravenous injection of the peptide-polymer conjugate and the control polymer to rats showed that the larger size of the nanotubes formed by the conjugate reduced renal clearance and elongated systemic circulation. Importantly, the ability to slowly disassemble into small units allowed effective clearance of the conjugates and reduced organ accumulation, making these materials interesting candidates in the search for effective drug carriers.
Introduction
Nanomedicine, and the use of drug delivery systems in particular, has been shown to reduce drug related side effects and thus to allow for higher drug dosing. and compared their behaviour to that of their spherical counterparts in mice models. 23 They
showed that large cylindrical structures of 2-18 µm in length enable much longer circulation times and higher loading of the anticancer agent Paclitaxel in comparison to spherical particles while maintaining similar tumour accumulation and survival rates. Müllner et al. have studied the pharmacokinetics of unimolecular cylindrical polymer brushes (with lengths ranking from 35 nm to 1200 nm) in rats, showing that they exhibit long term blood circulation, and that the aspect ratio of the brushes has a considerable impact on their pharmacokinetic parameters.
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They further studied this system in mouse xenografts, demonstrating that the brushes undergo EPR and passively target tumour tissues. 25 The main limitation of such large stable objects is their high stability in vivo leading to relatively poor clearance, which may lead to recognition by the mononuclear phagocytic system (MPS) translating to high accumulation in organs such as the spleen and the liver. 26 One way to circumvent this issue is to explore the use of materials which undergo supramolecular self-assembly, for example by directed hydrogen bonds formation. [27] [28] [29] Supramolecular polymers, 30 especially those that self-assemble in aqueous media, 31 have started to gain considerable attention in the field of nanomedicine. 27 They allow for a bottomup design strategy that enables extensive functionalization of the building blocks, resulting in broad libraries of assembled materials. Examples include systems based on host-guest interactions, 32 or on the stacking of peptide amphiphiles into fibres. [33] [34] [35] One possible major advantage of self-assembling structures over other nanoparticles is their supramolecular nature which provides initial stability, but eventually allows the structures to break up into unimeric entities small enough to be cleared out of the system, hence avoiding undesired organ
accumulation.
An emerging class of elongated drug carriers that feature such a supramolecular structure are nanotubes comprising cyclic peptide-polymer conjugates. 36 Cyclic peptides formed of an even number of alternating D-and L-amino acids have been shown to adopt a flat conformation leading to stacking into nanotubes through antiparallel β-sheet formation. 37 Conjugation of water-soluble polymers to these peptides enables control over the size and the functionality of the nanotubes. Although first cell studies indicated that nanotubes possess great potential as nanosized drug delivery systems, [38] [39] [40] their in vivo behaviour has yet to be explored.
Here, we synthesized poly(hydroxypropyl methacrylamide) (pHPMA)-based cyclic-peptide polymer conjugates and examined their ability to self-assemble into nanotubes. A nonassembling polymer which does not contain the peptide core was also synthesised as a control.
After selection of the most promising candidate, the in vitro behaviour of both conjugate and control polymer, as well as their pharmacokinetics and biodistribution in rats were studied and compared.
Results and discussion

Design and synthesis
The choice of a polymer that is pharmaceutically relevant is critical when designing a drug delivery vector, which is why pHPMA was chosen. During the past decades, pHPMA has been extensively studied in the context of cancer therapy 41 and several polymer-drug conjugates based on this polymer are in different stages of clinical trials. [42] [43] In addition to its high biocompatibility, pHPMA can be accessed by radical polymerization methods, which facilitates the introduction of comonomers and the formation of defined end-groups. Three pHPMA-cyclic peptide conjugates were synthesized, using Reversible Addition Fragmentation
Chain Transfer (RAFT) polymerization (see details in materials and methods section and supporting information) followed by coupling of the polymer to the chosen cyclic peptide, cyclo(D-Leu-Lys-D-Leu-Trp)2 (Scheme 1 and Table 1 ). Two different degrees of polymerization (DP) were targeted for HPMA homopolymers (P1, DP = 25 and P2, DP = 50). A third polymer (P3, DP = 50) incorporating a small percentage of a pyridine-containing comonomer (PUEMA), which provides a handle for attachment of organometallic drugs, was also prepared to test the influence of functional handles introduction in the system. organic base, to form a stable amide bond. [44] [45] [46] The obtained peptide-polymer conjugates C1-3
were purified by dialysis and isolated. Size exclusion chromatography (SEC) analysis revealed that low dispersities (≤ 1.20) were maintained (see Figure S1 for SEC chromatograms). 
Characterization of supramolecular nanotubes
Small angle neutron scattering (SANS) measurements were conducted on conjugates C1-3 in aqueous solution (deuterated PBS) in order to assess their self-assembly and elucidate key structural parameters, such as shape (using the q-dependency of the scattered intensity) and dimensions (using the intensity at low q values).
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Figure 1. A) Small angle neutron scattering profiles of C1 at 10 mg.mL -1 (orange squares), C2
at 5 mg.mL -1 (green diamonds), C3 at 5 mg.mL -1 (purple circles) in PBS and their fits using cylindrical micelle (orange line), Gaussian chain (green line) and flexible cylindrical micelle (purple line) models, respectively. B) Schematic representation of the three conjugates in solution.
Interestingly, all three conjugates exhibit very different scattering profiles ( Figure 1A ). Data for both homopolymer-based conjugates C1 and C2 show a plateau at low q values, indicative of a finite length, while a q -1 dependency is observed for C3 in that q range, characteristic of a longer cylindrical structure. In the case of C2, the data is best fitted with a Gaussian chain model, which represents non-assembled polymer chains in solution (see supporting information, Table S2 and Figure S2 ). In contrast, models corresponding to assembled structures were necessary to fit the data corresponding to the other two conjugates. More precisely, cylindrical micelle models (worm-like) were used to fit the data for C1 and C3, as they take into account both the cylindrical shape provided by the cyclic peptide core selfassembled into nanotubes (characteristic q -1 dependency at low q values: cylinder form factor) and the polymer arms (Gaussian chain form factor at high q values). 48 For these models, a radius of 5 Å was used for the peptide core, in accordance with previously reported results. 36 Using these parameters, reasonable values confirming the elongated shape of the structures were obtained (see supporting information, Tables S3 and S4 , Figures S3 and S4 ). In the case of C1 a nanotube length of about 5.2 nm was obtained, which corresponds to a aggregation number of 11, calculated using the previously reported distance between adjacent peptides 33, 40 (4.7 Å).
In the case of C3, precise information on length could not be obtained solely using SANS, therefore static light scattering (SLS) measurements were carried out in parallel to SANS in order to widen the window of observation and obtain scattering intensity values for lower q values ( Figure 2 ). Results show that the molecular weight of the assemblies was within the tested range independent of conjugate concentration and was found to be 6.15.10 5 ± 0.86.10 5 g.mol -1 (see Figure S5 and 49 Using this result together with the molecular weight of the unimer and the distance between adjacent peptides, an aggregation number of 34 ± 5, and an average length of 16.0 ± 2.3 nm, were determined. The aspect ratio of these nanotubes was estimated to be around 2.9 (see supporting information). It is important to note that this value is an estimate, as it is difficult to determine the dimensions of the polymeric shell in solution with accuracy.
The noticeable difference in assembly patterns for the three conjugates (see Figure 1B for a schematic representation) is likely due to the nature of the polymers attached to the cyclic peptide, with a combination of steric hindrance and hydrogen bonding capacity influencing the stacking of the conjugates. Comparing C1 and C2, which are based on different length homopolymers of HPMA (DP 25 and 53, respectively), it seems reasonable to conclude that the longer polymer chains in C2 hindered the self-assembly process, such that the conjugate C1 formed short cylinders (Nagg = 11) whereas C2 remained as unimers in solution. This result is in line with previously reported work, which showed a decrease in tube length with increasing polymer molecular weight, [50] [51] and with the general concept of frustrated growth of supramolecular systems induced by steric hindrance. 52 The differences in self-assembly between C2 and C3 are the most striking, since they have comparable molecular weights but contrasting morphologies in solution. The homopolymer-based C2 did not assemble while C3, which contains 5% of the comonomer PUEMA, stacked into elongated tubes (Nagg = 34 ± 5).
We attribute the differences in morphology to the presence of urea bonds and pyridine motifs in PUEMA, which provide additional hydrogen bonding and π-π stacking sites, respectively, thereby counterbalancing the steric hindrance caused by the long polymer chains, and strengthening the overall assembly.
In vitro studies
The interactions with cells of the nanotubes obtained from the self-assembly of C3 were investigated next.. A non-self-assembling polymeric equivalent (P4) was synthesized in a similar manner to P1-3 using a bifunctional CTA (see Scheme 1, Table S1 and materials and methods section for details on the synthesis, Table 1 and Figure S1 for for SEC results).
The biocompatibility of the conjugate C3 and the corresponding polymer control P4 was tested Cellular association of the nanotubes and of the non-assembling control was subsequently quantified using flow cytometry ( Figure 3D -F). To facilitate detection, a rhodamine monomer was copolymerized with HPMA and PUEMA following similar procedures to those used for the materials described above, to afford rhodamine-labelled conjugate C5 and polymer P6 with concentrations in rhodamine kept below 0.1 % of total monomer content (Scheme 2, see Scheme S1, Table S1 and materials and methods section for details on the synthesis, Table 1 and Figure S1 for SEC results.). The amount of rhodamine monomer was kept below 0.1 % of total monomer content to avoid disruption of the self-assembly process and interference with biological behaviour. Corrections factors were used to enable comparison between the two compounds, similar amounts of polymer were used in all cases and data was corrected according to fluorescence intensity (see supporting information, Figure S6 and Table S6 ). Cells were incubated in presence of the compounds for 3h and 24h at 37 °C. In both cases and in all three cell lines, the polymer control associated significantly less than the conjugate (p < 0.0001). For example in A2780, the amount of conjugate C5 measured in the cells was nearly double that of polymer P6 after 3h; the discrepancy increased to 3.5 times more conjugate after 24h incubation. We attribute this result to the difference in size and aspect ratio between the two systems, given the fact that the conjugates self-assemble in these conditions to form a cylindrical assembly with an average aggregation number of 34, whereas the polymer P6 remains as a single unit. Particle shape 53 and size [54] [55] [56] are thought to play a non-negligible role in cellular uptake, with larger particles exhibiting increased uptake, up to a certain size, above which the uptake generally decreases.
Although results vary across studies, uptake appears to be most efficient between 20 and 100 nm, with particles with a diameter of either less than 10 nm or more than 100 nm entering the cells less than those of intermediate size. This effect is found across particles of differing nature, including coated iron oxide, 54 silica 55 and polymeric 56 nanoparticles. The present results are in line with these findings, with 16 nm-long nanotubes entering the cells to a higher extent than single polymer chains.
Cellular association increases over time, indicating that uptake occurs to a greater extent than excretion. In the case of peptide-polymer conjugate C5, a 3-fold increase in fluorescence in MDA cells was observed when varying the incubation time from 3h to 24h. Similar increases were found in other cell lines, with 3.8x in PC3 and 3.9x in A2780. This effect was also observed for the polymer, although to a lesser extent, and increases in fluorescence of 2.4x 
Plasma pharmacokinetics and organ biodistribution
In order to quantitatively monitor the characterize the in vivo behaviour of the self-assembling peptide-polymer conjugates, both the conjugate C3 and corresponding control polymer P4
were radiolabelled, taking advantage of the hydroxyl groups present on pHPMA to attach
[14C]-ethanolamine (Scheme 3). Although the extent of labelling was kept below 1% of HPMA units to avoid any potential influence of the chemical modification, we cannot completely exclude an influence of the label on self-assembly or in vivo behaviour of the polymers or nanotubes Nevertheless, the chemical alteration induced by the radioactive labelling is minor and is not expected to alter the physical and bio-properties of the conjugates.
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Scheme 3. Radiolabelling of compounds C3 and P4.
The obtained compounds C3* and P4* were purified by size exclusion chromatography (SEC) and extensively dialysed to remove any excess radiolabel. Effective labelling was confirmed by HPLC analysis and scintillation counting of SEC fractions ( Figures S8 and S9) ; polymer P4* and conjugate C3* were found to have specific activities of 0.28 µCi/mg and 0.33 µCi/mg, respectively. The radiolabelled polymer P4* and conjugate C3* were subsequently injected intravenously to male Sprague Dawley rats at a dose of 12 mg.kg -1 and blood samples taken at regular intervals for 24h to determine the plasma concentration versus time profiles ( Figure 5 ).
Taking into account the weight (~ 300 g) and blood volume (~ 20 mL) of the Sprague Dawley rats, the 12 mg.kg -1 dose corresponds to 0.5 mg.mL -1 at the injection time, concentration at which the conjugates are assembled into 16-nm long tubes as determined by SLS (see above). mg.kg -1 (mean ± SD, n = 4-5 rats).
The non-compartmental (NC) pharmacokinetic parameters taken from the plasma profiles are summarized in Table 2 .
The initial volume of the central compartment (Vc) was close to blood volume, which is typical for high molecular weight materials that do not rapidly distribute out of the vasculature. The non-assembling polymer P4* showed relatively rapid clearance from the systemic circulation, in accordance with previously reported data for HPMA copolymers. [61] [62] [63] [64] In contrast, plasma exposure (AUC) of the nanotubes was significantly higher (>3 fold) than that of the polymer (p < 0.0001) and the increased exposure was reflected in reduced clearance (3 ± 0.2 mL.h -1 for the nanotubes vs 12 ± 0.4 mL.h -1 for the polymer). The terminal volume of distribution (Vd,β) was also significantly lower for the nanotubes (70 ± 2 mL for the nanotubes vs 225 ± 35 mL for the polymer chains). The combination of reductions in clearance and volume of distribution dictated that the elimination half-life of the nanotubes was relatively unchanged and only slightly longer than that of the polymer control. This parameter is calculated from the slope of the elimination phase that occurs after the rapid decrease of compound concentration during the distribution phase. In contrast to the distribution half-life, which corresponds to the distribution of compound from the blood circulation to the body tissues -it relates to drug metabolism and excretion, and is typically used to compare pharmacokinetic parameters. [65] [66] We attribute the differences in systemic pharmacokinetics between polymer P4* and conjugate C3* to the larger size of the nanotubes formed by C3*, which reduces distribution and allows them to partially avoid immediate renal clearance. The observed volume of distribution of the nanotubes is lower than for small molecular weight linear polymers, but higher than the reported values for PEGylated dendrimers (as low as 25 mL after 30h), 67 stars (approximately 60 mL after 7 days) 65 or small brushes (60 mL after 24h).
24 Table 2 . Calculated pharmacokinetic parameters and urine recovery after intravenous administration of conjugate C3* and polymer P4* to rats at 12 mg.kg -1 (mean ± SD, n = 4-5 rats). **p < 0.01, ****p < 0.0001. The percentage of dose recovery in urine after 24h was high for both the polymer chains (72 ± 8 %) and the conjugates (62 ± 7 %), indicating that the majority of both compounds is ultimately excreted from the body. The molecular weight cut-off for renal filtration is generally estimated to be around 50 kDa for hydrophilic polymers such as PEG or dextran 26 which is well below the molecular weight of the nanotubes (615 kDa, as determined by SLS) but above the mass of the polymer and the conjugate. Hence, this result suggests that the labelled compounds found in urine are fragments of the initial nanotubes, either degraded chemically (free radiolabel), or physically (unimeric conjugates or very short tubes).
Conjugate
In addition to the NC analysis the data was also fitted to a two-compartmental model (see materials and methods section and supporting information, Table S7 and Figure S10 ). Relevant pharmacokinetic parameters including t1/2, AUC, Vd and Cl calculated from the compartmental model correlated well with those derived from the NC analysis (Table S8 ). In particular, the higher AUC observed for the nanotubes is maintained, with 1007 ± 153 µg.mL -1 .h obtained using the two-compartmental model (vs 1120 ± 62 µg.mL -1 .h using the NC model), compared
to the values obtained for the polymer control (272 ± 68 µg.mL -1 .h and 331 ± 10 µg.mL -1 .h for the two-compartmental and NC models, respectively). These results indicate confidence in the comparisons between the polymer and conjugate using either approach.
To clarify the fate of both compounds after administration, and to verify that they were both largely excreted from the body within 24h, accumulation in major organs (liver, spleen, pancreas, kidneys, heart, lungs, brain) was quantified by measuring the residual [14C] content present in the ex vivo tissues harvested 24h after IV injection. (55 mCi/mmol, 0.1 mCi/mL) was obtained from ARC (American Radio Chemicals). All solvents were bought from commercial sources and used as received. Cyclic peptide and chain transfer agents CPAETC and E(CPAETC)2 were synthesized according to previously reported protocols.
Materials and methods
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Characterization methods
NMR spectra were recorded on a Bruker DPX-300 instrument. Molecular weights and dispersities of polymers were assessed by size exclusion chromatography (SEC) on a Polymer
Laboratories PL-GPC 50 Plus system in DMF with 0.1% LiBr, using a poly(methyl methacrylate) calibration, using refractive index detection. where θ is the scattered angle and λ is the incident neutron wavelength. The beam diameter was 8 mm. Samples were prepared at a concentration of 5 mg/mL in deuterated phosphate buffer saline (PBS), and were contained in 2 mm path length quartz cells. Each raw scattering dataset was corrected for the detectors efficiencies, sample transmission and background scattering and converted to scattering cross-section data ( Σ/ Ω vs. q) using the instrument software.
SANS was carried out either on the
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These data were placed on an absolute scale (cm -1 ) using the scattering from a standard sample (a solid blend of hydrogenous and perdeuterated polystyrene) in accordance with established procedures. 72 On the D11 instrument, scattering intensities were recorded by a two-dimensional positionsensitive 3 He detector. Three different instrument settings were used corresponding to a wave vector = 4 sin 2 ⁄ range of 0.01 < q < 0.5. H2O was used for instrumental calibration. The data were placed on an absolute scale (cm -1 ) using the scattering from a standard sample in accordance with established procedures. 73 The obtained reduced data was analysed with the open access software SASfit. 74 Light scattering measurements were obtained using an ALV-CGS3 system operating with a vertically polarized laser with a wavelength of 632 nm. The measurements were taken at 20°C over a range of angles (20-150 º). The incremental refractive index, dn/dC, was determined by measuring the refractive index of the polymer in water at various concentrations ranging from 0.25 to 2 mg/mL, using a Shodex RI detector operating at a wavelength of 632 nm.
Synthetic procedures
Synthesis of 2-hydroxypropyl methacrylamide (HPMA)
Adapted from Ulbrich et al. 75 Potassium carbonate (29 g, 1.1 eq., 0.21 mol) was dispersed in 120 mL of dry DCM. The mixture was cooled to -10°C with an ice-ethanol bath and 1-amino-2-propanol (14.5 mL, 1 eq., 0.19 mol) was added. Methacryloyl chloride (18.5 mL, 1 eq., 0.91 mol) was diluted with 20 mL of dry DCM, and added dropwise to the previous mixture, while maintaining the temperature at -10°C. Once the addition was complete, the reaction was left to warm up to room temperature and stirred overnight. After filtration and drying over MgSO4, the DCM was evaporated and a white solid was obtained. The product was dissolved in methanol and washed with hexane, and the methanol phase was evaporated. 
Synthesis of 2-(3-(pyridin-4-ylmethyl)ureido)ethyl)methacrylate (PUEMA)
RAFT polymer synthesis
Chain transfer agent (CTA, here CPAETC or E(CPAETC)2), monomers (HPMA, PUEMA, RhMA), initiator (VA 044) and solvent (70/30 DMSO/H2O) were introduced into a flask equipped with a magnetic stirrer and sealed with a rubber septum (see Table S1 for detailed conditions). The solution was degassed by bubbling nitrogen through it for 15 min, and then put in an oil bath at 44°C for the indicated time. Conversions were determined by 1 H NMR.
For polymers P5 and P6, conversion of RhMA could not be determined because the extremely low amounts did not allow visualization of the corresponding signals. The polymers were precipitated in ice-cold acetone and dried under vacuum. The rhodamine-labelled polymers P5
and P6 were further dialysed to remove any excess dye.
Conjugation of polymers to the cyclic peptide
General protocol: cyclic peptide, polymer (2.5 eq.) and HBTU (3.75 eq.) were solubilized in DMSO (1.5 mL). NMM (6 eq.) was added and the reaction mixture was left to stir at room temperature for 2 hours. After the reaction, DMSO was removed using a stream of N2 and the conjugates were dissolved in water and purified from the excess polymer using a centrifugal ultrafiltration unit with a molecular weight cut off of 30 kDa (Amicon ® Ultra centrifugal filter).
The isolated conjugates were freeze-dried.
Radiolabelling of compounds
Conjugate C3 (or polymer P4) was introduced in a vial, together with CDI (10 eq.) and anhydrous DMF (1 mL) and the mixture was stirred for 4 hours. An aliquot of [14C]-labelled ethanolamine in ethanol was withdrawn from the bottle (1 eq.) and the ethanol evaporated using a steam of nitrogen. DMF was used to redissolve the radiolabel and add it to the mixture, which was then stirred for 4 days. The solvent was removed using a stream of nitrogen and the driedup mixture was solubilized in water and passed over a size exclusion column (PD10, GE Healthcare Life Sciences) to remove most of the remaining free radiolabel prior to dialysis.
The purity of the radiolabelled compounds C3* and P4* was assessed by HPLC and size exclusion chromatography using PD10 cartridges ( Figures S8-9) . Briefly, 0.7 mL fractions were collected and the activity of each fraction was determined by scintillation counting. 
In vitro testing
Cells
Growth inhibition assay
Briefly, 5000 cells were seeded per well in 96-well plates and allowed to grow for 24 h before adding different concentrations of the compounds to be tested. Compounds were dissolved directly in cell culture medium at concentrations ranging from 0.1 to 500 μg/mL. Culture medium was replaced by dilutions of the compounds and cells further incubated for 72 h. After this, supernatant was removed and replaced by fresh medium. XTT assay was used to determine cell viability. Absorbance measurements of the plate at 475 nm were carried out using a Synergy HTX (Biotek) plate reader. Determination of viable treated cells was done in comparison to untreated controls. Two independent sets of experiments in triplicates were carried out and standard deviations were used for error bars.
Microscopy
Cells were seeded in an 8-chamber imaging plate (Eppendorf) at 15000 cells per well and incubated overnight at 37 °C with 5% CO2. Rhodamine-labelled conjugate dissolved in PBS was added to the wells to a final concentration of 20 μM and incubated for 24 h. Colocalization studies were carried out after lysosome staining using Lysotracker ® Green DND-26. Labelling was achieved by incubating cells in the presence of Lysotracker (100 nM) for 2 hours. The cells were washed 2 times with fresh media and images were recorded using a Leica SP5 Laserscanning confocal microscope with a HCX PL APO 40x (NA 1.25) oil objective. Images were acquired at 1024x1024, capturing rhodamine (ex 561; em: 565-580 nm), lysotracker GFP (ex 488; em 504-520 nm) and transmission channels. Image acquisition settings were consistent for samples and controls.
Flow cytometry
Cells were seeded in 24-well plates at 100 000 cells per well and incubated in 500 μL of compound-free media overnight at 37 °C with 5% CO2. Rhodamine-labelled compounds were then added to cells in triplicate, achieving a final concentration of 20 μM. Three sets of conditions were tested: incubation at 37 °C for 24 h, incubation at 37 °C for 3 h, and incubation at 4 °C for 3 h. For the incubation at 4 °C, the cells were placed on ice for 10 min prior to addition of the compound, and subsequently in the fridge. After incubation, the culture medium was removed, and the cells were washed with PBS, harvested with trypsin, transferred to Eppendorf tubes and spun at 1500 g for 5 min. The supernatant was discarded and cell pellets were resuspended in PBS, transferred into flow cytometry tubes and stocked on ice until measurement. Samples were analysed on a BD FACScan flow cytometer using the FL2 channel (585/42 nm). Cells were analysed using forward and side scatter gates to exclude debris and cell aggregates. Fluorescence intensity corresponding to untreated cells was subtracted, the data were processed using Flowing software 2 ® and reported values correspond to the average of the means of fluorescence for a population of 10000 cells.
Activity Determination and Scintillation Counting
The specific activity of the compounds was determined by dilution of known amounts of material into PBS. Aliquots were mixed with 4 mL of Ultima Gold and scintillation counted 
Intravenous Pharmacokinetic Studies
A day prior to compound administration, each rat was anaesthetised under isoflurane (2-5% v/v) and cannulas (polyethylene tubing 0.96 x 0.58 mm, Paton Scientific, Victor Harbour, Australia) surgically inserted into the right jugular vein and carotid artery (to facilitate IV administration and blood collection respectively) as previously described. 76 The rats were transferred to individual metabolic cages (to permit separate collection of urine and faeces) and bubbling had ceased. Ultima Gold (10 mL) was then added and the mixture vortexed before the samples were stored at 4 °C in the dark, without agitation, for at least 3 days prior to scintillation counting. Blank organs also were treated as above to provide for background correction. In order to correct for any reduction in radioactivity counting efficacy due to the processing of the tissues, an identical second set of samples was processed in the same way but the tissue homogenate aliquots were spiked with a known quantity of radiolabel prior to addition of Solvable. All samples were then scintillation counted at 12 C.
A processing efficiency was calculated, using the following equation:
Where spiked tissuedpm was the mass-corrected radioactivity measured in the spiked samples, tissuedpm,uncorr was the mass-corrected radioactivity in the non-spiked tissue samples, and spiked solndpm was the known amount of radioactivity added to the spiked sample. Effectively, the calculation provides an indication of the efficiency of counting, using the known (spiked) amount of radioactivity in each tissue as a reference. This value for efficiency was used to correct the [14C] content in the processed sample using the following equation:
The activity in the whole organ was then calculated knowing the mass fraction of the entire organ present in the processed sample. The results are expressed as either the percentage of injected dose in the organ at sacrifice or the percentage of injected dose per gram of tissue.
Urine
Urine, pooled from immediately after dose administration till 24h, was collected at the end of the study. A blank urine sample was also collected to provide for background correction. After accounting for the volume of pooled urine collected a 100 μL aliquot was taken and mixed with 4 mL of Ultima Gold and scintillation counted. After background subtraction, the radiolabel content of the sample was corrected for the total volume of urine collected and converted to a percentage of the total administered dose.
Calculation of Pharmacokinetic Parameters
The concentrations of radiolabel in plasma/whole blood samples were converted to microgram equivalent concentrations using the specific activity of the radiolabeled compounds. Noncompartmental pharmacokinetic parameters were calculated with Excel using the PK solver add-in. 77 The NCA IV Bolus model was used, in which the AUC0-∞ was calculated using the linear trapezoidal method. The elimination half-life (t1/2), volume of distribution (Vd) and clearance (Cl) were also determined from the model. 
